Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?

Nutrition Journal

Volumn 13, Issue 1, 2014, Pages

  Shema Didi, Lilach ^a   Kristal, Batya ^a,b   Sela, Shifra ^a,b,c   Geron, Ronit ^a   Ore, Liora ^c  

^a WESTERN GALILEE HOSPITAL   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

Hypertension; Lipid profile; Polyphenols; Pomegranate juice hemodialysis

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLANT MEDICINAL PRODUCT;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; FEMALE; HEMODIALYSIS; HUMAN; HYPERTENSION; INCIDENCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POMEGRANATE; POMEGRANATE JUICE; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BEVERAGE; BLOOD; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; DRUG EFFECTS; LYTHRACEAE; MIDDLE AGED; PHYTOTHERAPY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

LYTHRACEAE;

ADULT; AGED; ATHEROSCLEROSIS; BEVERAGES; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLACEBOS; PLANT PREPARATIONS; PUNICACEAE; RENAL DIALYSIS; RISK FACTORS; TRIGLYCERIDES;

EID: 84898548422     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-13-18     Document Type: Article

References (30)

1. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Kundhal K, Lok C, Nephron Clin Pract 2005 101 47 c52 10.1159/000086221 15942250 (Pubitemid 41208890)
2. Excerpts from the United State renal data system 2007 annual data report. Collins AJ, Foley R, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, Murray A, St Peter W, Xue J, Fan Q, Guo H, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Zhang R, Arko C, Chen SC, et al. Am J Kidney Dis 2008 51 1 320
3. Pattern of lipid profile in patients on maintenance hemodialysis. Maheshwari N, Ansari M, Darshana M, Lal K, Ahmed K, Saudi J Kidney Dis Transplant 2010 21 565 570
4. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Herspink H, Ninomiya T, Zoungas S, de- Zeeuw D, Grobbee D, Jardine M, Gallagher M, Roberts M, Cass A, Neal B, Perkovic V, Lancet 2009 373 1009 1015 10.1016/S0140-6736(09)60212-9 19249092
5. Impact of dyslipidemia in end-stage renal disease. Prichard S, J Am Soc Nephrol 2003 14 315 S320 10.1097/01.ASN.0000081698.10331.83 12939388
6. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low density lipoprotein formation. Deighan C, Caslake M, McConnell M, Boulton-Jones J, Packard C, Am J Kidney Dis 2000 35 852 862 10.1016/S0272-6386(00)70255-1 10793019 (Pubitemid 30238197)
7. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowring: data from the PROGRESS study. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A, Neal B, Macmahon S, Chalmers J, J Am Soc Nephrol 2007 18 2766 2772 10.1681/ASN.2007020256 17804673 (Pubitemid 47531204)
8. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Bloob pressure lowering treatment trialists' collaboration, Lancet 2000 356 1955 1964 11130523
9. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us? Fabbri G, Maggioni A, Adv Ther 2009 26 469 487 10.1007/s12325-009-0025- 6 19444394
10. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Seliger S, Weiss N, Gillen D, Kestenbaum B, Ball A, Sherrard D, Stehman-Breen C, Kidney Int 2002 61 297 304 10.1046/j.1523-1755.2002.00109.x 11786112 (Pubitemid 34075157)
11. Flavonoids as antioxidants: determination of radical-scavenging efficiencies. Bors W, Heller W, Michel C, Saran M, Methods Enzymol 1990 186 343 355 2172711 (Pubitemid 20279976)
12. Flavonoids- chemistry, metabolism, cardio protective effects and dietary sources. Cook N, Samman S, J Nutr Biochem 1996 7 66 76 10.1016/0955-2863(95) 00168-9 (Pubitemid 26086316)
13. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Aviram M, Dornfeld L, Atherosclerosis 2001 158 195 198 10.1016/S0021-9150(01)00412-9 11500191 (Pubitemid 32735484)
14. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, Volkova N, Presser D, Attias J, Liker H, Hayek T, Clin Nutr 2004 23 423 433 10.1016/j.clnu.2003.10.002 15158307 (Pubitemid 38811681)
15. Effects of pomegranate juice consumption on myocardial perfusion in patients with coronary heart disease. Summer M, Elliott-Eller M, Weidner G, Daubenmier J, Chew M, Marlin R, Raisin C, Ornish D, J Cardiol 2005 96 810 814 10.1016/j.amjcard.2005.05.026 (Pubitemid 41317656)
16. Concentrated pomegranate juice improves lipid profiles in diabetic patients with hyperlipidemia. Esmaillzadeh A, Tahbaz F, Gaieni I, Alavi-Majd H, Azadbakht L, J Med Food 2004 7 305 308 10.1089/jmf.2004.7.305 15383223 (Pubitemid 39299488)
17. Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Rosenblat M, Hayek T, Aviram M, Atherosclerosis 2006 187 363 371 10.1016/j.atherosclerosis.2005.09.006 16226266 (Pubitemid 43963016)
18. One year of pomegranate juice intake decreases oxidative stress, inflammation and incidence of infections in hemodialysis patients: a randomized placebo-controlled trial. Shema-Didi L, Sela S, Ore L, Shapiro G, Geron R, Moshe G, Kristal B, Free Radic Biol Med 2012 53 297 304 10.1016/j.freeradbiomed.2012. 05.013 22609423
19. The use of unequal randomisation ratios in clinical trials: a review. Dumville J, Hahn S, Miles J, Torgerson D, Contemp Clin Trials 2006 27 1 12 10.1016/j.cct.2005.08.003 16236557 (Pubitemid 41758434)
20. Colorimetry of total polyphenols with phosphomolybdic phosphotungstic acid reagents. Singleton V, Rossi J, Am J Emology Viticulture 1965 16 144 158
21. Quantitative determination of the polyphenols content pg pomegranate peel. Ben Nasr C, Ayed N, Metche M, Z Lebensum Unters Forsch 1996 203 374 378 10.1007/BF01231077 (Pubitemid 126798349)
22. Antioxidants for hypertension. Kitiyakara C, Wilcox C, Curr Opin Nephrol Hypertens 1998 7 531 538 10.1097/00041552-199809000-00008 9818200 (Pubitemid 28475292)
23. Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. Ignarro L, Byrns R, Sumi D, Nigris F, Napoli C, Nitric Oxide 2006 15 93 102 10.1016/j.niox.2006.03.001 16626982 (Pubitemid 44175887)
24. Pomegranate juice reduces oxidized low density lipoprotein downregulation of endothelial nitric oxide synthase in human coronary endothelial cell. Nigris F, Williams-Ignarro S, Botti C, Sica V, Ignarro L, Napoli C, Nitric Oxide 2006 15 259 263 10.1016/j.niox.2005.12.004 16413211 (Pubitemid 44466425)
25. Concentrated red grape juice exerts antioxidant, hypolipoidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. Castilla P, Echarri R, Davalos A, Cerrato F, Ortega H, Teruel J, Lucas M, Gomez-Coronado D, Ortuno J, Lasuncion M, Am J Clin Nutr 2006 84 252 262 16825703 (Pubitemid 44699192)
26. Consumption pf wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 associated with high density lipoprotein and stimulates its catalytic activities. Rock W, Rosenblat M, Miller-Lotan R, Levy A, Elias M, Aviram M, J Agric Food Chem 2008 56 8704 8713 10.1021/jf801756x 18759451
27. Paroxonase inhibits High-density lipoprotein oxidation and preserves its functions. Aviram M, Rosenblat M, Bisgaier C, Newton R, Primo-Parmo S, La Du B, J Clin Invest 1998 101 1581 1590 10.1172/JCI1649 9541487
28. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B, Am J Clin Nutr 2000 71 1062 1076 10799367 (Pubitemid 30230552)
29. Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR and AP-1 pathway activation. Shiner M, Fuhrman B, Aviram M, Atherosclerosis 2007 195 313 321 10.1016/j.atherosclerosis. 2007.01.007 17292903 (Pubitemid 350087961)
30. Paraoxonase 2 (PON2) attenuates macrophage triglyceride accumulation via inhibition of diacyglycerol acyltransferase 1, the rate limiting enzyme in triglycerides biosynthesis. Rosenblat M, Coleman R, Reddy S, Aviram M, J Lipid Res 2009 50 870 879 19091699